Sandoz 주식 가격. 0SAN - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

매수가

0.00

매도가

0.00

거래량

22,718

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

전일 종가

0.00

개장가

최근 거래 시간

41.79667

(O)

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

발행 주식

0.00

배당수익률

주가수익률

0.00

주당순이익(EPS)

매출

9.65B

순이익

77M

섹터

Med, Dental, Hosp Eq-whsl

산업

Med, Dental, Hosp Eq-whsl

웹사이트

www.sandoz.com

본부

Rotkreuz, Che

설립됨

Sandoz Group Ag is listed in the Med, Dental, Hosp Eq-whsl sector of the 런던증권거래소 with ticker 0SAN. The last closing price for Sandoz was CHF0. Over the last year, Sandoz shares have traded in a share price range of CHF 0.00 to CHF 0.00.

Sandoz currently has 0 shares in issue.

Francisco Ballester to retire; Peter Stenico appointed President Region International

Francisco Ballester to retire; Peter Stenico appointed President Region International Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange...

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference MEDIA RELEASE Strong first...

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio MEDIA RELEASE Afqlir®...

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0SAN - Frequently Asked Questions (FAQ)

What is the current Sandoz share price?

The current share price of Sandoz is CHF 0.00

What is the 1 year trading range for Sandoz share price?

Sandoz has traded in the range of CHF 0.00 to CHF 0.00 during the past year

What is the reporting currency for Sandoz?

Sandoz reports financial results in USD

What is the latest annual turnover for Sandoz?

The latest annual turnover of Sandoz is USD 9.65B

What is the latest annual profit for Sandoz?

The latest annual profit of Sandoz is USD 77M

What is the registered address of Sandoz?

The registered address for Sandoz is SUURSTOFFI 14, ROTKREUZ, ROTKREUZ, 6343

What is the Sandoz website address?

The website address for Sandoz is www.sandoz.com

Which industry sector does Sandoz operate in?

Sandoz operates in the MED, DENTAL, HOSP EQ-WHSL sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
EUZEuropa Metals Ltd	1.55p (29.17%)	736.05k
SYMESupply@me Capital Plc	0.0042p (25.37%)	1.14B
CRTACirata Plc	23.95p (21.79%)	605.3k
ARKArkle Resources Plc	0.35p (16.67%)	1.6M
EQTEqtec Plc	0.605p (15.24%)	13.64M
BIOMBiome Technologies Plc	1.50p (-60.00%)	537.45k
ZEDZenova Group Plc	0.275p (-35.29%)	6.75M
UKOGUk Oil & Gas Plc	0.0115p (-34.29%)	1.61B
RCGHRc365 Holding Plc	1.05p (-30.00%)	14.77M
VIDVidendum Plc	46.65p (-24.76%)	6.62M
UKOGUk Oil & Gas Plc	0.0115p (-34.29%)	1.61B
NTVONativo Resources Plc	0.0015p (-16.67%)	1.55B
TRPTower Resources Plc	0.0275p (7.84%)	1.16B
SYMESupply@me Capital Plc	0.0042p (25.37%)	1.14B
LLOYLloyds Banking Group Plc	67.20p (1.97%)	272.15M

3331 3 분 전

BIEL + DR. OZ + RFK = $$$
BIOELECTRONICS FLAGSHIP PRODUCT - ACTIPATCH - ON DR. OZ:
Dr. Oz devoted a whole program to explaining PEMF Pulsed ElectroMagnetic Field technology - with audience members wearing Actipatches (BIEL's flagship product) - saying it is changing the practice of med

3331 3 분 전

TomD2046 4 분 전

Looks like 2 sellers, or maybe it was same one, market sold 400k shares today and mm's took it below the ask which was at .0001 down to .000001

End of the day the bid was

FBEC

arizona1 6 분 전

We'll have to find out from local state governments and hospitals, not from Kennedy and Trump..

dinogreeves 6 분 전

I don't know. Weird as it is.

SMCI

Dodger1 6 분 전

You all know what's important...you can put things/thoughts/idea forward..but always the question...is your
question more important than mine?

Go $AABB

AABB

€LL-$G7$ 6 분 전

🗑 trash can full of poop

GGSM

getmoreshares 7 분 전

https://pbs.twimg.com/media/GkWw4vJW8AEdqjm?format=jpg&name=small

Investor082 8 분 전

You don't have to justify your trading activity, LOL! I understand there is no way to make money with this stock by staying long. In fact, you’d have lost over 90% value over the last 10-12 years.

Make sure you don't complain about manipulation once LP disappoints post UK approval an

NWBO

getmoreshares 8 분 전

https://pbs.twimg.com/media/GkWw4vJW8AEdqjm?format=jpg&name=small

dheminger 9 분 전

I agree as long as everyone in the BOD stays with the mindset of non-dilutive financing we could go anywhere from these numbers..$ATWT

ATWT

littlejohn 9 분 전

What info did he get to change his tune

against delinquent filing companies?...

so we watch...LJ

SMCI

The_Pro 10 분 전

style="font-size: 16px"Seems like multiple ActiPatch.com's out there. Turnkey. Very very smart. Use BioElectronics Corps ActiPatch.com but modified.
style="font-size: 16px"

style="font-size: 16px"ActiPatch.za
style="font-size: 16px"ActiPatch.co.za

BIEL

jhdf51 11 분 전

Pretty nice ride

COOP

XMaster2023 11 분 전

NICE does not approve the treatment!

NWBO

gorbec1 11 분 전

Well I think mcic and us are
https://youtu.be/ufw9dVys3t0

MCIC

PickStocks 12 분 전

Show us the MONEY!!!!!!!!!

COOP

StockHobit 12 분 전

CEOS is taking Kate to court.

CEOS

JuicePigs 13 분 전

There is no news on this ticker..dead in the water...even the pumpers have started to go belly up as they sold a week ago and moved to CFSU.

CFSU

littlejohn 13 분 전

ot: democratic supporters control most of

media that is released...

nothing unexpected with negative tilt...

In April, when the retail sales number for

March come out should be a hint of how

things are doing as weather gets b

SMCI

sam1933 14 분 전

✅️💹🚀Canary Funds has filed an S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) for an exchange-traded fund (ETF) tied to HBAR, the native asset of the Hedera blockchain.

Interesti

HBARUSD

SuperLogisticsMan 14 분 전

Okie Dokie....

CYBL

BDEZ 17 분 전

Hooters to prepare for bankruptcy, per Bloomberg.

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Sandoz Group Ag (0SAN) 시세

Sandoz Group Ag (0SAN)

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

Sandoz Group Ag 정보

0SAN 최신 뉴스

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz reports first quarter 2024 sales

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

0SAN - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE